Requiring an amyloid-beta(1-42) biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials

L.S. Schneider, R.E. Kennedy, G.R. Cutter, N.C. Fox

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)367-377
JournalAlzheimers & Dementia
Volume6
Issue number5
DOIs
Publication statusPublished - 2010

Cite this

@article{498507b54c244b17be9aa136d4c3aeaf,
title = "Requiring an amyloid-beta(1-42) biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials",
author = "L.S. Schneider and R.E. Kennedy and G.R. Cutter and N.C. Fox",
year = "2010",
doi = "10.1016/j.jalz.2010.07.004",
language = "Undefined/Unknown",
volume = "6",
pages = "367--377",
journal = "Alzheimers & Dementia",
issn = "1552-5260",
publisher = "Elsevier",
number = "5",

}

Requiring an amyloid-beta(1-42) biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials. / Schneider, L.S.; Kennedy, R.E.; Cutter, G.R.; Fox, N.C.

In: Alzheimers & Dementia, Vol. 6, No. 5, 2010, p. 367-377.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Requiring an amyloid-beta(1-42) biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials

AU - Schneider, L.S.

AU - Kennedy, R.E.

AU - Cutter, G.R.

AU - Fox, N.C.

PY - 2010

Y1 - 2010

U2 - 10.1016/j.jalz.2010.07.004

DO - 10.1016/j.jalz.2010.07.004

M3 - Article

VL - 6

SP - 367

EP - 377

JO - Alzheimers & Dementia

JF - Alzheimers & Dementia

SN - 1552-5260

IS - 5

ER -